Payment overview · 2025
General Payments
$363.87
13 reported records · 10 companies
Healthcare provider profile · identity verified
Chad H Meshberger, DO
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CONCORD, NH · NPI 1306167424
Verified facts
What the public records show
CMS Open Payments records show Chad H Meshberger, DO received $363.87 in general payments during 2025 across 13 reported records.
Eisai Inc. accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ubrelvy by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REYVOW as an associated drug or biological on 378 records involving 290 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Reyvow by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $108.80 | 29.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.55 | 13.9% | 3 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $40.92 | 11.2% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $26.65 | 7.3% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $25.64 | 7.0% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $24.93 | 6.8% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $23.86 | 6.6% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $22.50 | 6.2% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $20.03 | 5.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.99 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $363.87 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $108.80 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $40.92 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.88 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | REYVOW open payments reported associated product |
CMS Open Payments — General Payments 378 supporting records · 290 recipient NPIs · example record 1186470979 |
Reyvow · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 109 | 29 |
| Aimovig Autoinjector | Erenumab-Aooe | 108 | 17 |
| Gabapentin | Gabapentin | 106 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 84 | 24 |
| Pregabalin | Pregabalin | 68 | 18 |
| Memantine Hcl | Memantine Hcl | 66 | 18 |
| Briviact | Brivaracetam | 65 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 21 |
| Lamotrigine | Lamotrigine | 52 | 11 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Modafinil | Modafinil | 43 | 12 |
| Donepezil Hcl | Donepezil Hcl | 42 | 15 |
| Ubrelvy | Ubrogepant | 41 | suppressed |
| Xcopri | Cenobamate | 38 | suppressed |
| Carbamazepine Er | Carbamazepine | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Primidone | Primidone | 37 | 12 |
| Topiramate | Topiramate | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 36 | suppressed |
| Lacosamide | Lacosamide | 36 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 36 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 15 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Reyvow | Lasmiditan Succinate | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $363.87 · 13 records | Eisai Inc. | BOTOX, Dysport, EPIDIOLEX, KISUNLA, Leqembi, Nayzilam, Ocrevus Zunovo, QULIPTA, UBRELVY, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VYALEV, ZEPOSIA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ubrelvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error